يعرض 1 - 20 نتائج من 282 نتيجة بحث عن '(((( ai large decrease ) OR ( _ ((parp decrease) OR (nn decrease)) ))) OR ( via linear decrease ))', وقت الاستعلام: 0.49s تنقيح النتائج
  1. 1

    Inotodiol decreases clone formation in HCC cells. حسب Yushuang Xing (20636685)

    منشور في 2025
    "…In addition, inotodiol showed to induce apoptosis, characterized by an increase in Bax expression, a decrease in Bcl-2, Bcl-XL and MCL1 expression, the initiation of cleaved PARP1 and cleaved caspase 3, and inhibition of the MAPK/ERK pathway. …"
  2. 2
  3. 3

    Data Sheet 1_Emotional prompting amplifies disinformation generation in AI large language models.docx حسب Rasita Vinay (21006911)

    منشور في 2025
    "…Introduction<p>The emergence of artificial intelligence (AI) large language models (LLMs), which can produce text that closely resembles human-written content, presents both opportunities and risks. …"
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    The results of linear mixed model. حسب Soheila Qanbari (20455173)

    منشور في 2024
    "…This study aimed to assess whether enhancing M1 and S1 excitability via tDCS, alongside sensory-motor exercises, offers additional benefits for CLBP patients.…"
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    PARP9 knockdown promotes apoptosis and DNA damage. حسب Yating Li (1819822)

    منشور في 2024
    "…(E) DNA damage in GC cells significantly increased post-PARP9 knockdown as determined by comet assay. (F) The anti-DNA damage capacity of GC cells decreased markedly following reduction of PARP9 expression. …"
  18. 18
  19. 19

    Data Sheet 1_Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients.pdf حسب Maria Delgado-Ortet (8840702)

    منشور في 2025
    "…In this work, we developed noninvasive imagingbased measurements of spatial and longitudinal heterogeneity in a retrospective analysis of a phase 2 non-randomized study of germline BRCA1/BRCA2 mutated (gBRCAm) ovarian cancer patients treated with combination of PARP inhibitors (PARPi) and immune checkpoint inhibitors (ICIs).…"
  20. 20